New hope for patients with stubborn blood disorder
NCT ID NCT05885555
Summary
This study is testing an experimental drug called ianalumab for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets, increasing the risk of bleeding. It is for people whose ITP hasn't been controlled well by at least two standard treatments. The main goal is to see if the drug can safely and effectively raise and maintain platelet counts over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Med Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Garran, Australian Capital Territory, 2605, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Giessen, 35392, Germany
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Johor Bahru, 80100, Malaysia
-
Novartis Investigative Site
Katowice, 40-519, Poland
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
Aydin, Efeler, 09100, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, Fatih, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Edirne, Merkez, 22030, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kocaeli, 41380, Turkey (Türkiye)
-
Novartis Investigative Site
Glasgow, G31 2ER, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.